TipRanks
NeoPharm Co., Ltd. (KR:092730)
:092730
South Korea Market
092730
NeoPharm Co., Ltd.
RESEARCH TOOLSreports

NeoPharm Co., Ltd. (092730) Income Statement

― Followers

NeoPharm Co., Ltd. Income Statement

Last quarter (Q1 2026), NeoPharm Co., Ltd.'s total revenue was ₩36.22B, an increase of 14.60% from the same quarter last year. In Q1, NeoPharm Co., Ltd.'s net income was ₩8.62B. See NeoPharm Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
₩ 132.18B₩ 119.01B₩ 97.10B₩ 85.03B₩ 87.93B
Gross Profit
₩ 84.71B₩ 74.03B₩ 65.39B₩ 58.38B₩ 62.39B
Operating Expenses
₩ 55.94B₩ 49.37B₩ 40.08B₩ 36.94B₩ 39.96B
Depreciation and Amortization
₩ 3.10B₩ 3.15B₩ 1.62B₩ 1.62B₩ 1.50B
EBITDA
₩ 31.88B₩ 33.40B₩ 31.01B₩ 24.95B₩ 25.37B
Operating Income
₩ 28.77B₩ 24.65B₩ 25.31B₩ 21.44B₩ 22.43B
Other Income/Expenses
₩ 3.49B₩ 5.56B₩ 4.07B₩ 1.88B₩ 1.40B
Pretax Income
₩ 32.26B₩ 30.21B₩ 29.37B₩ 23.32B₩ 23.84B
Net Income
₩ 27.82B₩ 23.06B₩ 23.21B₩ 17.03B₩ 17.71B
Per Share Metrics
Basic EPS
₩ 1.78K₩ 1.47K₩ 1.48K₩ 1.09K₩ 1.13K
Diluted EPS
₩ 1.78K₩ 1.47K₩ 2.97K₩ 1.09K₩ 1.13K
Weighted Average Shares Outstanding
 15.64M 15.64M 7.82M 7.82M 7.82M
Weighted Average Shares Outstanding (Diluted)
 15.64M 15.64M 7.82M 7.82M 7.82M
Currency in KRW

NeoPharm Co., Ltd. Earnings and Revenue History